[A case of pembrolizumab responding to recurrent small bowel mucinous adenocarcinoma with Peutz-Jeghers syndrome]

Nihon Shokakibyo Gakkai Zasshi. 2021;118(11):1063-1070. doi: 10.11405/nisshoshi.118.1063.
[Article in Japanese]

Abstract

An advanced small bowel mucinous adenocarcinoma with Peutz-Jeghers syndrome was resected, and we started capecitabine plus oxaliplatin (CapeOX) as adjuvant therapy. However, local recurrence was noted, and the tumor increased even after CapeOX plus bevacizumab and fluorouracil plus leucovorin plus irinotecan plus panitumumab (FOLFIRI plus panitumumab). Pembrolizumab was administered after confirming high-frequency microsatellite instability, and the tumor shrank markedly and remained shrunk for 20 months.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma, Mucinous* / drug therapy
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bevacizumab / therapeutic use
  • Camptothecin / therapeutic use
  • Colorectal Neoplasms*
  • Fluorouracil / therapeutic use
  • Humans
  • Leucovorin / therapeutic use
  • Neoplasm Recurrence, Local
  • Peutz-Jeghers Syndrome* / drug therapy

Substances

  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • pembrolizumab
  • Leucovorin
  • Fluorouracil
  • Camptothecin